natgillin/translations-raw huggingface dataset:
the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragment thereof. A hybridoma capable of producing the antibody of any one of claims 1-18. A conjugate comprising an antibody of any one of claims 1-18 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 135 i varijabilno područje lakog lanca koji ima aminokiselinsku sekvencu od SEQ ID NO: 142 naznačeno time da navedena nukleinska kiselina kodira polipeptid, poželjno protutijelo, koje je sposobno vezivati se za CLD18A2 ali ne za CLD18A1 i nakon vezanja za CLD18A2 posreduje u uništavanju stanica koje eksprimiraju CLD18A2 od strane T stanica.
is selected from the series consisting of hydrogen, halogen and (C1-C4)-alkyl; 
R3 se bira iz skupine koju čine vodik, halogen i (C,-C4)-alkil;
The mouse of claim 33 or claim 34, wherein the first nucleotide sequence is operably linked to endogenous mouse H-2K regulatory elements, and the second nucleotide sequence is operably linked to endogenous mouse B2 microglobulin regulatory elements. 
Miš iz zahtjeva 33. i 34., pri čemu je prvi nukleotidni slijed operabilno povezan s endogenim mišjim H-2K regulatornim elementima, a drugi je nukleotidni slijed operabilno povezan s endogenim mišjim regulatornim elementima B2 mikroglobulina.
It is to be understood that when is a group (1-6C)alkyl substituted by, for example amino to give for example a 2-aminoethyl group, it is the (1-6C)alkyl group that is attached to the group X1 (or the quinazoline ring when X1 is a direct bond). 
(1-6C)alkilna skupina supstituirana, na primjer, aminoskupinom pri čemu nastaje 2-aminoetilna skupina, da je baš ta (1-6C)alkilna skupina ona koja je vezana na skupinu X' (ili na kinazolinski prsten kada je X! izravna veza)
Additionally, the use of two different types of hydroxypropylcellulose in form of a mixture allows to obtain the expected stability, release profiles and bioavailability of the combination composition of the invention, while reducing the number of process steps. A combination pharmaceutical composition in the form of a uniform solid blend consisting of: a granulate comprising candesartan cilexetil, polyethylene glycol and excipients selected from the group consisting of a filler, a disintegrant, a binder and mixtures thereof, wherein the weight ratio of candesartan cilexetil to polyethylene glycol is in a range from 5.0:1.0 to 2.0:1.0, and 
Kombinirani farmaceutski pripravak u obliku ujednačene čvrste smjese koja sadrži: a) = granulat koji sadrži kandesartan cileksetil, polietilen glikol i pomoćne tvari odabrane iz skupine koja sadrži punilo, sredstvo za raspadanje, vezivo i njihove smjese, pri čemu je težinski omjer kandesartan cileksetila prema polietilen glikolu u rasponu od 5.0:1.0 do 2.0:1.0,1 b) - ekstragranularnu fazu koja je praškasta smjesa koja sadrži amlodipin ili njegovu farmaceutski prihvatljivu sol i pomoćne tvari odabrane iz skupine koja sadrži punilo, sredstvo za povećanje skliskosti i njihove smjese, ili iz skupine koja sadrži sredstvo za raspadanje, sredstvo za povećanje skliskosti i njihove smjese.
HIV infection 
HIV infekcija Thimopentin
The furniture panel as claimed in claim 21, characterized in that the furniture panel is composed of wood, wood-based materials, wood-substitute materials, plastic, metal, glasses, stone, ceramic or a combination thereof. 
Ploča za namještaj prema zahtjevu 15, naznačena time što se materijali ploče za namještaj sastoje od drveta, drvenih materijala, materijala koji su zamjena za drvo, plastike, metala, kamena, keramike ili njihovih kombinacija.
The compound or composition for use of claim 3, wherein the disease or disorder is large bowel cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom Jajnika.
Use of EPO-R Agonist Peptides of the Invention 
Datum podnošenja europske prijave patenta:
System according to claim 10, wherein the concentrator (C) is adapted to perform the operations of 
Sustav prema patentnom zahtjevu 10, pri čemu je sabirnik (C) prilagođen za provođenje operacija
A method for producing compounds expressed by the general formula 1.1.2, as defined in claim 3, which consists in reaction between (R)-stereoisomers of the relevant diester 2.4 and 4-cyano-3-trifluoromethyl-benzyl isothiocyanate 3.3 at elevated temperatures, wherein R2 and R3 are as defined above. 
Metoda za proizvodnju spojeva koja su prikazana općom formulom 1.1.2, kao što je definirano u patentnom zahtjevu 3, koji se sastoji u reakciji između (R)-stereoizomera relevantnog diestra 2.4 i 4-cijano-3-trifluorometil-benzil izotiocijanata 3.3 pri povišenim temperaturama, Q Ha
The flexible hose that in the known dispenser connects the container to the tap head is a disposable part for one-off use. 
Fleksibilna cijev koja u poznatom raspršivaču spaja spremnik na glavu za istjecanje je zamjenjivi dio za jednokratnu upotrebu.
A vaccine kit for concomitant or sequential administration comprising two multi-valent immunogenic compositions for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae and Neisseria meningitidis, said kit comprising a first container comprising: tetanus toxoid (TT), 
Cjepivni komplet za istodobnu ili uzastopnu primjenu, naznačen time što sadrži dva polivalentna imunogena pripravka za postizanje zaštite kod domačina protiv bolesti koje uzrokuju bakterije Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, te Haemophilus influenzae, gdje navedeni komplet sadrži prvi spremnik, koji sadrži: tetanusni toksoid (TT), t>&
The processes of the invention give IL-2/SDS microaggregates that are suitable for pharmaceutical use in humans, and so the invention provides a pharmaceutical composition comprising IL-2/SDS microaggregates of the invention. 
Procesi iz izuma daju IL-2/SDS mikroagregate koji su prikladni za farmaceutsku uporabu kod ljudi, i tako izum daje farmaceutski sastav koji sadrži mikroagregate IL-2/SDS iz izuma.
The method of claim 1, wherein the combination contains isobutylamides from Echinacea angustifolia and gingerol from Zingiber officinale in weight ratios ranging of 1:0:5. 
Kombinacija za upotrebu kao što je prijavljena u patentnom zahtjevu 3, naznačena time da sadrži izobutilamide iz Echinacea angustifolia i gingerol i Zingiber officinale u masenom omjeru raspona od 1:1 do 1:0.5.
said pellet is lysed using homogenization, solvent extraction, bead mill, freeze/thaw cycles, ultrasonication or enzymatic lysis; 
ta granula se lizira putem homogenizacije, ekstrakcije otapalom, kuglastog mlina (bead mill), ciklusima smrzavanja/odmrzavanja, ultrazvučno ili enzimatskom lizom;
The method of claim 1, wherein the endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. 
Miš prema patentnom zahtjevu 1, naznačen time, što lokus endogenog mišjeg lakog lanca K sadrži a) = graničnu sekvencu lokusa humanog lakog lanca koja se proteže od hVA3- 12 do hV23-1; b) graničnu sekvencu lokusa humanog lakog lanca A koja se proteže od hV2A3- 27 do hV23-1; ili c) = graničnu sekvencu lokusa humanog lakog lanca A koja se proteže od hVA5- 52 do hV2A1-40 1 graničnu sekvencu lokusa humanog lakog lanca X koja se proteže od hVA3-29 do hV23-1.
Combination of at least three different pharmaceutically active substances or their physiologically acceptable salts selected from the group of anticholinergics, glucocorticoids, and B2-adrenoceptor agonists for the treatment of inflammatory diseases. 
PATENTNI ZAHTJEVI 1. Kombinacija R.R-glikopirolata roliprama i budesonida ili njihovih fiziološki prihvatljivih soli, naznačena time, da se koristi za liječenje upalnih oboljenja.
The unit dosage form according to claim 6, wherein following oral administration the unit dosage form, is more than 50% dissolved in the stomach prior to being released into the small intestines. 
Jedinični dozirni oblik prema zahtjevu 6, gdje se nakon oralne primjene jediničnog dozirnog oblika više od 50% otapa u želucu prije oslobađanja u tanko crijevo.
The compound or a pharmacologically acceptable salt thereof according to claim 1, wherein in formula (I), Ar1 and Ar2 each independently represent a heteroaryl group, R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group or a C3-C7 cycloalkyl group, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a C1-C6 alkyl group or a halogenated C1-C6 alkyl group, and the substituent on the heteroaryl group is one or two groups selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxyl group, a hydroxy C1-C6 alkyl group, a C3-C7 cycloalkyl group, an amino group, a C1-C3 alkylamino group and a di-C1-C3 alkylamino group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, pri čemu u formuli (I), Ar1 i Ar2 svaki nezavisno predstavlja heteroaril grupu,, R2 i R3 svaki nezavisno predstavlja atom vodika, atom halogena, C1-C6 alkil grupu, halogeniranu C1-C6 alkil grupu ili C3-C7 cikloalkil grupu, i R5 svaki nezavisno predstavlja atom vodika, atom halogena, C1-C6 alkil grupu ili halogeniranu C1-C6 alkil grupu, i supstituent na heteroaril grupi je jedna ili dvije grupe odabrane iz grupe koja se sastoji od atoma halogena, C1-C6 alkil grupe, halogenirane C1-C6 alkil grupe, hidroksilne grupe, hidroksi C1-C6 alkil grupe, C3-C7 cikloalkil grupe, amino grupe, C1-C3 alkilamino grupe i di-C1-C3 alkilamino grupe.
A beneficial effect of vaginally applied ascorbic acid has been claimed (see US patent 5,371,107) in the treatment or prevention of certain bacterial infections, where the pH lowering effect of ascorbic acid plays a role in inhibiting the bacterial growth of strains like Gardnerella or E. coli (see Petersen E., Gyne 3, 1998), responsible of infections like bacterial vaginosis. 
Koristan učinak vaginalno primijenjene askorbinske kiseline je patentiran (vidi US patent 5,371,107) u liječenju ili prevenciji određenih bakterijskih infekcija, gdje učinak snižavanja pH askorbinskom kiselinom igra ulogu u inhibiciji bakterijskog rasta sojeva kao Gardnerella ili £. coli (vidi Petersen E., Gyne 3, 1998.), odgovornih za infekcije kao bakterijske vaginoze.
Accordingly, such beam-like blocks of wood of the process according to the invention preferably have a length of >1,500 mm, preferably > 2,500 mm. 
U skladu s tim, poželjno je da blokovi od drva, koji imaju oblik grede i koji se obrađuju po postupku koji je u skladu s ovim izumom, imaju duljinu od > 1,500 mm, poželjno > 2,500 mm.
A method of preparing a solution for intravenous infusion, comprising: providing a lyophilised formulation according to claim 12, adding water to form a reconstituted solution, and diluting said reconstituted solution with an aqueous system. A method according to claim 37, wherein the compound is the compound of formula (II) (PM00104): 
Metoda pripremanja otopine za intravensku infuziju, naznačena time, što uključuje: osiguravanje fiole koja sadrži liofilizirani spoj prema bilo kojem od zahtjeva 1 do 2 1 disaharid, dodavanje vode da se formira rekonstituirana otopina i razblaživanje spomenute rekonstituirane otopine vodenim sustavom Metoda prema zahtjevu 20, naznačena time, što je spoj PM00104.
A compound represented by Formula 1, and salts thereof, for use in a method for the treament of an inflammatory disorder: wherein: 
Spoj, naznačen time, da je predstavljen sljedećom formulom I, i njegove soli, te time da se upotrebljava u postupku liječenja upalnog poremećaja:
Pressure tank, according to claim 1 or 2, characterized in that the elements in the central inner part (S), which are having contact with a working medium, are made of a material not more than 3 mm thick. 
Tlačni spremnik u skladu s patentnim zahtjevom 1 ili 2, naznačen time što su elementi u središnjem donjem dijelu (S), koji su u kontaktu s radnim medijem, načinjeni od materijala debelog najviše 3 mm.
A lyophilised pharmaceutical composition which, when reconstituted with 1.2 ml sterile water for injection, contains in each millilitre: 1.1 mg non-glycosylated des-alanyl-1, serine-125 human IL-2; 50 mg mannitol; 0.18 mg sodium dodecyl sulfate (SDS); 0.17 mg monobasic sodium phosphate; and 0.89 mg dibasic sodium phosphate to pH 7.5, wherein the IL-2 and SDS are in the form of aggregates such that the reconstituted composition has a specific turbidity (t) less than 1.1 cm2/g. 
Liofilizirani sastav prema patentnom zahtjevu 11, naznačen time, da kada je rekonstituiran s 1,2 ml sterilne vode za injektiranje, u svakom mililitru sadrži: 1,1 mg ne-glikoziliranog des-alanil-1, serin-125 humanog IL-2; 50 mg manitola; 0,18 mg natrijevog dodecil sulfata (SDS); 0,17 mg monobazičnog natrijevog fosfata; i 0,89 mg dibazičnog natrijevog fosfata do pH 7,5, kod čega su IL-2 i SDS u obliku agregata, tako da rekonstituirani sastav ima specifičnu zamućenost (7) manju od 1,1 cm?/g.
The veterinary or agricultural composition of claim 1, wherein in the dihydroazole compound of formula (I) is selected from the following: 
Veterinarski ili agrikulturni sastav prema zahtjevu 1, naznačen time, da je spoj dihidroazola formule (I) odabran od sljedećih:
and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, or halogen; 
Rg i Ry su nezavisno odabrani od vodika, alkila, cikloalkila, alkenila, arila, heterociklila, alkoksi, ariloksi, ili halogena; ili njegova farmaceutski prihvatljiva sol ili solvat.
A human antibody or antigen-binding fragment of claim 1, which specifically binds human NGF with a KD of 0.5 pM or less. 
Humano antitijelo ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se specifično veže na humani NGF uz KD od 0,5 pM ili manje.
Moreover, two patients showed total suppression of PPR. 
Još k tome, kod dva pacijenta je došlo do potpune supresije PPR-a.
The method according to claim 17, wherein the pro-form of the proNGF mutant is cleaved by a protease. The method according to claim 19, wherein the pro-form of the proNGF mutant is cleaved by a serine protease. 
Postupak prema zahtjevima 4-7, naznačen time da se pro-oblik proNGF mutanta cijepa djelovanjem proteaze, poželjno djelovanjem serin proteaze, poželjnije djelovanjem tripsina.
A process for preparing a compound of formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; said process comprising the steps of 
(1) gdje je RI vodikova ili dušikova zaštitna grupa; spomenuti postupak sadrži sljedeće korake (1) priprema spoja sa formulom (4), ili njegove soli,
separating the A9-tetrahydrocannabinol from the resulting phase containing the A9-tetrahydrocannabinol; and 
razdvajanjem A9-tetrahidrokanabinola iz dobivene faze koja sadrži A9-tetrahidrokanabinol; i
A counter according to claim 25 or 26, wherein each of said first and second pawls is arranged such that: 
Brojač u skladu sa patentnim zahtjevom 21 ili 22, gdje je svaka od navedene prve i druge zapinjače organizirana tako da:
the fixing means (or fasteners) do not interfere with the catching means (or catches) of the latches when the latches are in their idle position such that the ladle shroud is free to move away from the collector nozzle along the longitudinal axis, and 
- sredstva za pričvršćivanje (31, 314) ne utječu na sredstva za zahvaćanje (33, 334) zasuna, kada su zasuni u svom položaju praznog hoda tako da se izljevnik (111) može odmaknuti od mlaznice kolektora duž uzdužne osi,
The methods comprise administering to the patient an effective amount of a tumor associated peptide, a nucleic acid, or an expression vector of the present invention, wherein the amount of the peptide, nucleic acid or expression vector is effective to provoke an anti-target cell immune response in the patient. 
Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te Tarmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
The process according to claim 6, characterized in that heat treatment of the feed mixture, which contains the fatty acid mixture, is carried out in an expander, preferably in the presence of an emulsifier. 
Krmna smjesa za preživače prema zahtjevu 1 ili 2, naznačena time što je ukupna količina mješavine masnih kiselina u hrani 10,1 – 50%.
where R2, R11, R12 and P3 are as defined in Table 1 above and R10 is an alkyl group such as a methyl or ethyl group. 
OH gdje su R2, Ri, Ri2 i Pz kao što je definirano u tabeli 1 gore, a Ryg je alkil skupina kao stoje metil ili etil skupina.
According to a preferred variant of embodiments 21) to 40), the product obtained after step a) is not isolated and steps a) and b) are performed in the same reactor (that is, the 2-step process is performed as a so-called “one-pot process”). 
Postupak prema jednom od zahtjeva 12 do 14, naznačen time, da se ne izolira produkt koji se dobiva nakon koraka a), a koraci a) i b) se izvode u istom reaktoru.
• psychosis triggered or exacerbated by severe mental stress; and 
* - psihozom aktiviranom ili pogoršanom snažnim mentalnim stresom; te
or a salt or solvate thereof. 
ili njegova sol ili solvat.
The use according to claim 9 for the prophylaxis and/or treatment of non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus and other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Uporaba prema patentnom zahtjevu 11 za profilaksu i/ili tretman ne-malignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, specifično hepatocelularnog karcinoma, adenoma debelog crijeva i polipoze, adenokarcinoma debelog crijeva, raka dojke, adenokarcinoma pankreasa, Barrett-ovog ezofagusa i drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
A controlled-release, cannabinoid dosage form suitable for 8-hour, 12-hour, or 24 hour dosing in a human patient comprising a pharmaceutically-acceptable matrix comprising a therapeutically-effective amount of trans-(±)-A9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable controlled-release material for use as a medicament for oral administration. 
Oblik doziranja kanabinoida s kontroliranim otpuštanjem prikladan za 8-satno, 12-satno, ili 24 satno doziranje kod humanog pacijenta koji sadrži farmaceutski prihvatljivu matricu koja sadrži terapeutski učinkovitu količinu trans-(±)-A9-tetrahidrokanabinola u kristalnom obliku i farmaceutski prihvatljivu tvar za kontrolirano otpuštanje za upotrebu kao lijeka za oralnu primjenu.
The method according to claim 1, wherein the amount of ciclesonide administered is a daily dose. 
Uporaba prema zahtjevu 1, 4 ili 5, naznačena time, da se primjenjuje količina ciklesonida kao dnevna doza.
circuitry adapted to communicate with said remote location in detecting a second phase relation between a wiring phase voltage at said relay location and a wiring phase voltage at said remote location; circuitry adapted to receive phase relation information; and 
- < krug adaptiran za komunikaciju sa spomenutom udaljenom lokacijom u otkrivanju drugog faznog odnosa između faznog napona vodiča na spomenutoj relejnoj lokaciji i faznog napona vodiča na spomenutoj udaljenoj lokaciji; naznačen time, da obuhvaća
Method according to claims 15-16 wherein 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide is radiolabelled with carbon-11 on the carbon of the methyl group located on position 5 of the indole nucleus. 
Postupak u skladu s patentnim zahtjevima 15-16, naznačen time što je 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamid radioaktivno obilježen ugljikom-11 na ugljiku u metilnoj skupini koja se nalazi na položaju 5 u indolskoj jezgri.
recovering said antibodies, or one of their functional fragments or derivatives from the culture medium or said cultured cells. 
izolaciju rečenih antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met iz medija za kulturu ili rečenih kultiviranih stanica.
is H. Compounds of the formula I as claimed in claim 1 or 2 in which 
R7jeH. Spojevi formule T u skladu s patentnim zahtjevom 1 ili 2, gdje
In Formula (I), R represents a group represented by CR1R2R3, an unsubstituted or substituted C6-10 aryl group, or a cyano group; 
(ID naznačen time što, u Formuli (II), R predstavlja skupinu koja je predstavljena s CR'R*R*, nesupstituiranu ili supstituiranu skupinu C4_19 aril, ili cijano skupinu;
recycling at least a portion of said naphtha to a hydrogen generator to form a hydrogen rich syngas stream, wherein said hydrogen generator comprises a steam methane reformer (44), an autothermal reformer (60) or a combination thereof; and combining said hydrogen-rich syngas stream with the hydrogen-lean syngas stream and feeding the combined syngas stream to the Fischer-Tropsch reaction to enhance synthesis of hydrocarbons. 
(c) recikliranja u najmanju ruku dijela navedene nafte u generator vodika kako bi se dobilo struju sinteznog plina bogatu vodikom, gdje navedeni generator vodika sadrži parni metanski reformer (44), autotermalni reformer (60) ili njihovu kombinaciju; i (d) kombiniranja navedene struje sinteznog plina bogate vodikom sa strujom sinteznog plina siromašnom vodikom i dodavanjem kombinirane struje sinteznog plina u Fischer-Tropschovu reakciju kako bi se poboljšalo sintezu ugljikovodika.
The preferred method for the manufacture of this composition is advantageous, because both phases of the method, i.e. 
Prednost poželjnog postupka proizvodnje ovog pripravka što se obje faze u ovom postupku, tj.
Blood samples were taken at 1, 3, 5, 7.5, 10, 15, 20, 25, 30, 45 and 60 minutes after injection and were assayed for IL-2 bioactivity. 
Uzorci krvi uzeti su kod 1, 3, 5, 7,5, 10, 15, 20, 25, 30, 45 i 60 minuta nakon injektiranja i analizirani su na bioaktivnost IL-2.
isolating the anti-human alpha-synuclein antibody or human alpha-synuclein-binding fragment thereof from the cell culture. 
izoliranje navedenog protutijela ili njegovog fragmenta iz kulture.
at least one anti-reflection layer formed on the photoelectric conversion substrate; and two or more transparent inorganic dielectric layers formed on the anti-reflection layer(s), wherein the two or more transparent inorganic dielectric layers comprise at least one first transparent inorganic dielectric layer consisting of an oxide of titanium. 
najmanje jedan prvi transparentni anorganski dielektrični sloj koji se sastoji od titanijevog oksida; i drugi transparentni anorganski dielektrični sloj odabran iz skupine koja se sastoji od cinkovog oksida premazanog aluminijem, indij-kositar oksida, oksida cinka i nitrida silicija, s indeksom refrakcije koji se kreće od 1,5 do 2,0.
wherein R9 is selected from the group consisting of morpholino, 2,6-dimethylomorpholino, 1,1-dioxothiomorpholino, 4,4-difluoropiperidynyl and 3-methoxyazetidin-1-yl; or 
polovica azetidinila B3 pri čemu je R9 odabran iz skupine koja se sastoji od morfolina, 2,6- dimetilomorfolina, 1,1-dioksotiomorfolina, 4,4-difluoropiperidinila i 3- metoksiazetidin-1-ila; ili